<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383887</url>
  </required_header>
  <id_info>
    <org_study_id>2014p001033D</org_study_id>
    <nct_id>NCT03383887</nct_id>
  </id_info>
  <brief_title>DAW1033D in Obstructive Sleep Apnea</brief_title>
  <acronym>OSAstimD</acronym>
  <official_title>Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment
      options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
      activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
      to normal subjects. In this protocol the investigators will test the effect of DAW1033D
      administered before sleep on OSA phenotype traits and OSA severity during sleep.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">December 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea hypopnea Index (AHI, events/hour of sleep)</measure>
    <time_frame>1 night</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collapsibility of the upper airway: Passive and Active V0 (L/min) genioglossus muscle responsiveness to increased ventilatory drive (GG%max/cmH2O).</measure>
    <time_frame>1 night</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Obstructive Sleep Apnea (OSA)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule 30 minutes before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAW1033D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DAW1033D capsule 30 minutes before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo before sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAW1033D oral capsule</intervention_name>
    <description>DAW1033D before sleep</description>
    <arm_group_label>DAW1033D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - AHI &gt; 15

        Exclusion Criteria:

          -  Any medical condition other than well controlled hypertension, diabetes,
             hyperlipidemia

          -  Any medication known to influence breathing, sleep/arousal or muscle physiology.

          -  Claustrophobia.

          -  Inability to sleep supine.

          -  Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.

          -  Individuals with underlying cardiac disease, such as arrhythmias.

          -  Individuals taking psychiatric medications, or any of the studied medications for
             medical care.

          -  History of seizures

          -  For women: Pregnancy.

          -  History of panic disorder / hyperventilation syndrome / Attention
             deficit-hyperactivity disorder (ADHD) / autism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sleep Disorders Research Program Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Taranto-Montemurro, MD</last_name>
      <phone>617-732-6541</phone>
      <email>ltarantomontemurro@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Andrew Wellman</investigator_full_name>
    <investigator_title>Associate professor HMS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

